1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Genentech’s PFS Data May Help Inavolisib Compete In PI3KCA-Mutated Breast Cancer

 
• By Joseph Haas

Inavolisib meets statistical significance for progression-free survival in HR+/HER2- advanced breast cancer with a PI3KCα mutation, which could set up competition with Piqray, Ibrance and Kisqali.

Genetech
Genentech's inavolisib may offer a new treatment option in HR+/HER2- breast cancer • Source: Shutterstock: Michael Vi

Genentech, Inc. may have taken a strategically important step in the treatment of HR+/HER2- advanced breast cancer with a PI3KCA mutation on 5 December with pivotal data showing that its inavolisib can provide statistically significant progression-free survival (PFS) versus a comparator regimen.

Key Takeaways

  • Genentech’s inavolisib demonstrates a progression-free survival benefit in HR+/HER2-negative breast cancer.

  • The Phase III study used a comparator containing established breast cancer agent Ibrance,...

While the Roche Holding AG division did not share numerical data from the Phase III INAVO120 study, Genentech announced that inavolisib demonstrated a statistically significant and clinically meaningful improvement...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.